Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Advanced Medical Isotope Corporation (the "Company") appointed Thomas J. Clement to its Board of Directors, effective September 11, 2012. Mr. Clement received 250,000 stock options with an exercise price of $0.21 and an expiration date of September 5, 2015.

The Board has determined that Mr. Clement is an independent director under the Company's independence guidelines. There are no arrangements or undertakings between Mr. Clement and any other persons pursuant to which he was elected as a director of the Company. There are no family relationships between Mr. Clement and any director, executive officer or any person nominated or chosen by the Company to become a director or executive officer. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Mr. Clement and the Company.

Clement has over 30 years experience in product development engineering, engineering management, and senior management. In 1998 Clement co-founded Pathway Medical Technologies, Inc. ("Pathway"), serving as its Chief Executive Officer. Pathway was acquired by Bayer Healthcare of Germany in 2011.

The full text of the press release issued in connection with the announcement is set forth in Exhibit 99.1 which is attached hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. Exhibit Number Description 99.1 Press Release, dated September 11, 2012.

---